Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncomed Pharma (OMED)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,381
  • Shares Outstanding, K 38,630
  • Annual Sales, $ 38,150 K
  • Annual Income, $ -39,060 K
  • 36-Month Beta 1.86
  • Price/Sales 0.62
  • Price/Cash Flow N/A
  • Price/Book 0.57
  • Price/Earnings ttm 4.81
  • Earnings Per Share ttm 0.16
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.37
  • Prior Year 0.25
  • Growth Rate Est. (year over year) -188.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.70 +27.14%
on 01/22/19
0.97 -8.25%
on 02/15/19
+0.13 (+17.11%)
since 01/15/19
3-Month
0.55 +61.82%
on 12/26/18
1.60 -44.38%
on 11/23/18
-0.51 (-36.43%)
since 11/15/18
52-Week
0.55 +61.82%
on 12/26/18
3.62 -75.41%
on 03/09/18
-1.21 (-57.62%)
since 02/15/18

Most Recent Stories

More News
Fighting Cancer at the Root: VeraStem and Propanc Biopharma

TORONTO, ON / ACCESSWIRE / January 23, 2019 / The Wealthy Venture Capitalist (or "WVC"), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known...

CELG : 90.69 (+0.01%)
OMED : 0.89 (+15.58%)
PPCB : 0.0150 (-0.66%)
BAYN : 0.0150 (+50.00%)
BLCM : 3.17 (+0.96%)
INO : 3.70 (+0.27%)
VSTM : 3.30 (+7.14%)
CLLS : 17.45 (+2.17%)
Corelogic Inc Has Returned 24.8% Since SmarTrend Recommendation (CLGX)

SmarTrend identified a Downtrend for Corelogic Inc (NYSE:CLGX) on July 26th, 2018 at $51.30. In approximately 4 months, Corelogic Inc has returned 24.83% as of today's recent price of $38.56.

CTT : 9.43 (+0.86%)
EPAY : 47.96 (+1.98%)
EXAS : 88.55 (+0.49%)
WYNN : 124.51 (+0.87%)
HMSY : 32.21 (+3.01%)
GLT : 13.95 (+2.72%)
MHK : 139.21 (+0.30%)
BBW : 5.03 (+1.00%)
CDW : 94.84 (+1.05%)
COUP : 96.33 (+1.17%)
QTWO : 66.79 (-0.09%)
DENN : 17.74 (+0.91%)
MYL : 31.84 (+1.02%)
DFRG : 8.37 (-1.53%)
GCAP : 7.04 (+3.23%)
FEYE : 17.23 (-1.82%)
MXIM : 55.85 (+0.11%)
POL : 32.80 (+2.53%)
AN : 39.08 (+2.09%)
TWO : 13.89 (+0.43%)
HUBG : 45.73 (+0.75%)
AR : 9.61 (+5.95%)
RE : 216.93 (+1.35%)
NNBR : 10.35 (+0.58%)
ARE : 134.86 (+0.72%)
CVI : 42.58 (+1.16%)
CERS : 6.47 (+3.52%)
NDAQ : 87.76 (+0.69%)
ELLI : 98.90 (+0.15%)
BLDR : 13.62 (+0.74%)
EGRX : 41.90 (+3.38%)
RGLD : 87.19 (-0.32%)
PRGO : 48.95 (+0.72%)
PENN : 24.41 (-0.29%)
NTAP : 64.03 (+0.58%)
IBM : 138.03 (+1.14%)
NTRI : 43.33 (+0.32%)
BANR : 60.82 (+3.35%)
CWT : 50.93 (+0.16%)
STAA : 36.42 (+3.55%)
ATHN : 134.99 (+0.01%)
CL : 66.48 (+1.57%)
TFSL : 16.93 (+1.26%)
UFPI : 32.23 (+1.00%)
SDRL : 8.66 (+4.34%)
GOV : 6.87 (-5.50%)
HQY : 77.10 (+1.74%)
IPGP : 154.88 (+3.56%)
MINI : 36.07 (+0.08%)
CMTL : 27.20 (+0.93%)
CHD : 64.69 (+0.53%)
GPI : 61.77 (+3.90%)
HRL : 43.20 (+0.35%)
RARE : 56.65 (+2.15%)
MLI : 32.39 (+1.25%)
GPS : 25.07 (+0.60%)
CHS : 5.68 (+3.09%)
RYAM : 14.09 (+2.47%)
PBI : 7.05 (+0.86%)
NUVA : 58.59 (+0.15%)
IMDZ : 1.44 (-1.37%)
CAMP : 14.57 (+2.61%)
NOC : 286.98 (+2.27%)
AEL : 32.77 (+5.00%)
EBIX : 58.57 (+0.97%)
DISCA : 29.30 (+1.84%)
GPOR : 8.04 (+4.28%)
BGS : 26.21 (+0.77%)
TECH : 191.63 (+1.63%)
PCH : 35.47 (+1.31%)
NOV : 29.81 (+2.69%)
TECD : 104.15 (+0.97%)
DISCK : 27.65 (+1.69%)
DECK : 146.29 (+2.54%)
NOW : 234.89 (+0.37%)
MGLN : 64.82 (+2.08%)
IEX : 144.12 (+2.15%)
PTC : 91.93 (+1.03%)
AVT : 44.12 (+0.23%)
RGS : 18.36 (-0.16%)
BSFT : 54.95 (+0.09%)
FOSL : 14.88 (-2.43%)
WAL : 46.00 (+2.13%)
IVR : 15.97 (+0.19%)
ENR : 45.63 (+0.20%)
ISBC : 12.65 (+1.12%)
SHOO : 34.41 (+0.17%)
HDP : 14.68 (+1.80%)
AWK : 98.05 (+0.82%)
OMED : 0.89 (+15.58%)
LADR : 17.56 (+0.11%)
BIG : 32.27 (+0.34%)
WY : 25.54 (+0.47%)
JBLU : 17.96 (-0.66%)
GNMK : 6.31 (+3.95%)
FORM : 15.93 (+0.50%)
PFSI : 22.86 (+1.51%)
NEWM : 13.63 (+1.56%)
KFRC : 38.13 (+2.94%)
HOLX : 46.29 (+2.34%)
TMK : 83.36 (+1.87%)
AXTA : 26.68 (+0.79%)
PGEM : 21.65 (unch)
CLH : 60.04 (+1.13%)
CLI : 21.08 (+0.33%)
NRG : 42.46 (-0.35%)
CLGX : 39.74 (+0.97%)
SFLY : 46.07 (+0.37%)
ICUI : 253.28 (+1.38%)
CARA : 17.05 (+3.02%)
WTR : 35.62 (-0.08%)
NTGR : 35.60 (+0.74%)
OLED : 118.49 (+0.95%)
VNDA : 21.11 (+4.92%)
HIBB : 17.62 (-0.23%)
FFBC : 27.98 (+2.79%)
DLTR : 98.85 (+0.32%)
EQT : 18.93 (+4.01%)
OMER : 14.04 (-2.16%)
KTOS : 16.95 (unch)
SRCL : 45.56 (+1.18%)
GES : 20.45 (+0.15%)
KMX : 62.06 (+1.47%)
PLAB : 11.43 (+0.09%)
NCS : 7.67 (-1.29%)
MAR : 121.05 (+2.05%)
MRVL : 18.83 (-1.88%)
UAL : 88.31 (+0.18%)
CNK : 37.31 (+0.32%)
NATH : 74.29 (+3.61%)
TPH : 13.09 (+0.08%)
OCUL : 3.66 (-0.27%)
SKYW : 55.68 (-0.84%)
HIVE : 4.43 (+1.84%)
GAIA : 11.61 (+2.47%)
ESRX : 92.33 (-3.62%)
PHM : 27.12 (+0.78%)
EBS : 66.16 (+1.77%)
CACI : 180.06 (+1.04%)
SAVE : 61.67 (+0.41%)
EZPW : 10.02 (+1.01%)
TPX : 56.99 (+1.62%)
KLAC : 108.19 (+0.98%)
ULTA : 306.36 (+0.45%)
WWE : 87.46 (-1.59%)
ESV : 4.78 (+6.46%)
LTRPA : 16.68 (-1.18%)
DAL : 51.08 (+1.19%)
BMY : 51.67 (+1.65%)
ECL : 163.48 (+1.16%)
CHRW : 91.45 (+0.83%)
WWW : 39.58 (+2.59%)
ETH : 19.76 (+1.28%)
IART : 51.06 (+0.81%)
LE : 17.51 (+1.92%)
LH : 150.17 (+2.32%)
HZO : 19.61 (+5.49%)
MTD : 668.86 (+0.90%)
OSTK : 19.73 (+2.92%)
LDOS : 63.37 (+1.67%)
SAGE : 160.93 (+1.80%)
CIEN : 40.21 (+1.26%)
MTW : 17.47 (+3.19%)
AMC : 13.79 (+1.03%)
NDLS : 7.51 (-0.66%)
EFII : 27.59 (+0.91%)
SIVB : 246.95 (+2.73%)
MU : 41.99 (-0.57%)
DSW : 27.47 (+0.29%)
VRNT : 52.39 (+0.42%)
OII : 16.65 (+3.29%)
SAFM : 121.10 (+0.53%)
DATA : 129.34 (-0.52%)
TLYS : 11.86 (+0.42%)
TREE : 316.65 (+2.49%)
TRUP : 29.26 (+5.98%)
AMCX : 64.46 (+2.25%)
EXPD : 73.64 (-0.43%)
SUPN : 39.10 (+2.25%)
NBIX : 84.32 (-0.27%)
SAIC : 76.59 (+2.71%)
CBM : 37.68 (+5.25%)
BURL : 162.81 (+0.33%)
AMED : 136.22 (-1.81%)
EXPR : 5.29 (+1.73%)
SBH : 18.71 (+0.11%)
ATSG : 24.90 (+3.02%)
PLT : 49.62 (+3.53%)
QDEL : 65.43 (+1.76%)
NLNK : 1.53 (+3.38%)
STMP : 201.24 (+1.90%)
IPCC : 142.80 (+0.32%)
BMTC : 39.73 (+2.58%)
STML : 11.49 (+3.42%)
EGL : 29.10 (+0.24%)
LUV : 57.70 (-0.52%)
CCL : 57.25 (+0.26%)
INOV : 15.00 (+5.49%)
COTY : 11.04 (-0.36%)
MGM : 28.21 (+3.07%)
AKBA : 6.65 (+2.78%)
LGIH : 60.37 (+0.62%)
CDNS : 52.58 (+1.78%)
CRZO : 12.68 (+4.11%)
TEN : 36.25 (+6.03%)
HAIN : 17.76 (+1.78%)
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals

EQNX::TICKER_START (Nasdaq:OMED),(LSE:MPH.L), EQNX::TICKER_END

OMED : 0.89 (+15.58%)
Recent Analysis Shows Construction Partners, OptimizeRx, OncoMed Pharmaceuticals, Issuer Direct, Red Violet, and Golden Minerals Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Construction Partners, Inc....

OPRX : 12.81 (-2.21%)
ROAD : 11.86 (+3.85%)
RDVT : 7.38 (-1.99%)
OMED : 0.89 (+15.58%)
ISDR : 12.25 (-0.41%)
AUMN : 0.30 (-3.23%)
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody

Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage Solid Tumors

OMED : 0.89 (+15.58%)
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that interim results of its...

OMED : 0.89 (+15.58%)
OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights

Q1 Cash Balance of $88.4 Million--Cash through Q3 2019

OMED : 0.89 (+15.58%)
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y

Acorda's (ACOR) earnings and revenues lag estimates in Q1. The company reiterates its 2018 outlook for the key drug Ampyra.

LGND : 120.86 (-0.02%)
OMED : 0.89 (+15.58%)
INFI : 1.39 (+2.21%)
ACOR : 14.30 (-8.10%)
OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report...

OMED : 0.89 (+15.58%)
Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y

Allergan's (AGN) first-quarter 2018 earnings surpass estimates with revenues also marginally beating the same. Moreover, the company ups its adjusted earnings and sales view for the full year.

LGND : 120.86 (-0.02%)
AGN : 139.07 (+0.29%)
OMED : 0.89 (+15.58%)
INFI : 1.39 (+2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade OMED with:

Business Summary

OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal...

See More

Key Turning Points

2nd Resistance Point 1.08
1st Resistance Point 0.99
Last Price 0.89
1st Support Level 0.78
2nd Support Level 0.66

See More

52-Week High 3.62
Fibonacci 61.8% 2.45
Fibonacci 50% 2.09
Fibonacci 38.2% 1.72
Last Price 0.89
52-Week Low 0.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar